Vanda Pharmaceuticals Inc.
Price Action
Technical Summary
CONSOLIDATINGVanda Pharmaceuticals Inc. is in a consolidation phase, trading with mixed signals as moving averages converge. Relative strength is weak (RS Rating: 41), showing significant lag compared to the market leaders. Earnings contraction of 64% provides fundamental context to the price action. Investors should exercise caution due to high volatility (82% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $6.02 | -0.21% | BELOW |
| 50 SMA | $6.41 | -6.28% | BELOW |
| 100 SMA | $7.00 | -14.13% | BELOW |
| 150 SMA | $6.94 | -13.35% | BELOW |
| 200 SMA | $6.43 | -6.49% | BELOW |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is VNDA in an uptrend right now?
VNDA has a trend score of 2/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 2 of 4 trend criteria are met.
Is VNDA overbought or oversold?
VNDA's RSI (14) is 42. The stock is in neutral territory, neither overbought nor oversold.
Is VNDA outperforming the market?
VNDA has a Relative Strength (RS) Rating of 41 out of 99. VNDA is currently lagging the broader market.
Where is VNDA in its 52-week range?
VNDA is trading at $6.01, which is 60% of its 52-week high ($9.94) and 32% above its 52-week low ($4.14).
How volatile is VNDA?
VNDA has a Beta of 0.89 and 52-week volatility of 82%. It's less volatile than the S&P 500 - generally more stable.